Cantor Fitzgerald Comments on PACB FY2025 Earnings

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Pacific Biosciences of California in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechnology company will post earnings per share of ($0.62) for the year. The consensus estimate for Pacific Biosciences of California’s current full-year earnings is ($0.91) per share.

Other research analysts have also recently issued research reports about the company. Scotiabank dropped their price target on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research report on Monday, November 11th. StockNews.com upgraded Pacific Biosciences of California to a “sell” rating in a research note on Thursday, January 9th. Piper Sandler raised their price objective on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the company a “neutral” rating in a research report on Monday, November 11th. Finally, UBS Group cut Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $2.95.

Pacific Biosciences of California Trading Up 6.5 %

NASDAQ:PACB opened at $1.81 on Wednesday. Pacific Biosciences of California has a 12 month low of $1.16 and a 12 month high of $7.50. The company has a current ratio of 9.74, a quick ratio of 8.64 and a debt-to-equity ratio of 1.97. The firm’s 50 day moving average is $1.89 and its 200 day moving average is $1.82. The stock has a market capitalization of $495.69 million, a PE ratio of -1.24 and a beta of 1.95.

Institutional Investors Weigh In On Pacific Biosciences of California

Large investors have recently modified their holdings of the stock. ARK Investment Management LLC raised its stake in Pacific Biosciences of California by 0.6% in the third quarter. ARK Investment Management LLC now owns 33,406,401 shares of the biotechnology company’s stock worth $56,791,000 after buying an additional 193,947 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Pacific Biosciences of California by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 6,327,906 shares of the biotechnology company’s stock worth $10,759,000 after acquiring an additional 225,034 shares in the last quarter. State Street Corp lifted its stake in shares of Pacific Biosciences of California by 5.7% in the 3rd quarter. State Street Corp now owns 6,276,156 shares of the biotechnology company’s stock valued at $10,669,000 after purchasing an additional 340,766 shares during the period. Soros Fund Management LLC lifted its stake in shares of Pacific Biosciences of California by 23.6% in the 3rd quarter. Soros Fund Management LLC now owns 2,098,000 shares of the biotechnology company’s stock valued at $3,567,000 after purchasing an additional 400,000 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Pacific Biosciences of California by 4.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,040,303 shares of the biotechnology company’s stock valued at $3,469,000 after purchasing an additional 82,807 shares in the last quarter.

Insider Buying and Selling at Pacific Biosciences of California

In other Pacific Biosciences of California news, insider Oene Mark Van sold 34,405 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $2.03, for a total transaction of $69,842.15. Following the transaction, the insider now directly owns 1,597,454 shares of the company’s stock, valued at approximately $3,242,831.62. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.